<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159700</url>
  </required_header>
  <id_info>
    <org_study_id>PRJ1-3024 CS101</org_study_id>
    <nct_id>NCT05159700</nct_id>
  </id_info>
  <brief_title>A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, First-In-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhuhai Yufan Biotechnologies Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhuhai Yufan Biotechnologies Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety&#xD;
      and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the safety, tolerability, PK, and pharmacodynamics of PRJ1-3024 and&#xD;
      will determine the maximum tolerated dose in subjects with advanced solid tumors.&#xD;
&#xD;
      PRJ1-3024 will be evaluated as an oral therapeutic that tests the anti-tumor activity of&#xD;
      PRJ1-3024 in patients with solid tumors and has not yet been tested in humans.&#xD;
&#xD;
      This study will find the safe and tolerable recommended dose in subjects with advanced solid&#xD;
      tumors as a open-label, 3+3 dose escalation study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1, open label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period</measure>
    <time_frame>Day 1 to Day 21</time_frame>
    <description>Safety listings and pharmacokinetic listings will be used for evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Characterized by type, seriousness, relationship to study treatment, timing, and severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter： Accumulation ratio</measure>
    <time_frame>24 months</time_frame>
    <description>to estimate the accumulation of PRJ1-3024 from time 0 to the time of last quantifiable concentration after multiple administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>estimated by the proportion of subjects having a complete response (CR) or partial response (PR) with use of RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>defined as time from the first occurrence of a documented objective response to the time of relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter：AUC（0-last）</measure>
    <time_frame>24 months</time_frame>
    <description>Area under the concentration-time curve AUC from time 0 to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter：Maximum observed concentration (Cmax)</measure>
    <time_frame>24 months</time_frame>
    <description>assessed as time from time 0 to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>Monotherapy Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRJ1-3024</intervention_name>
    <description>PRJ1-3024 is provided as capsules and is administered orally once a day.</description>
    <arm_group_label>Monotherapy Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced (unresectable) or&#xD;
             metastatic r/r solid tumors for which no standard therapy is available or for whom&#xD;
             standard therapy is considered unsuitable or intolerable.&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female subjects age ≥18 years.&#xD;
&#xD;
          -  ECOG Performance Status 0~2.&#xD;
&#xD;
          -  Has at least 1 measurable lesion as defined by RECIST 1.1 criteria .&#xD;
&#xD;
          -  Life expectancy of &gt;3 months, in the opinion of the Investigator.&#xD;
&#xD;
          -  Able to take oral medications and willing to record daily adherence to investigational&#xD;
             product.&#xD;
&#xD;
          -  Adequate hematologic parameters unless clearly due to the disease under study.&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
          -  Able to understand and willing to sign a written informed consent form.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of another malignancy&#xD;
&#xD;
          -  Known symptomatic brain metastases requiring &gt;10 mg/day of prednisolone.&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Known active HBV, HCV, AIDS-related illness.&#xD;
&#xD;
          -  Has received a live vaccine within 30 days&#xD;
&#xD;
          -  History of active autoimmune disorders or ongoing immunosuppressive therapy.&#xD;
&#xD;
          -  Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors&#xD;
             or inducers of cytochrome P450 3A (CYP3A) .&#xD;
&#xD;
          -  Prior treatment with hematopoietic progenitor kinase 1 (HPK1) inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Ouyang</last_name>
    <role>Study Director</role>
    <affiliation>Sr. VP, R&amp; D</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jourdan Flynn</last_name>
    <phone>7607991332</phone>
    <email>jflynn@vanguardclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anthony Vandross, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in human</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <keyword>Recommended Phase 2 dose</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Hematopoietic progenitor kinase 1</keyword>
  <keyword>PRJ1-3024</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

